Patents by Inventor Alexandra Zanin-Zhorov
Alexandra Zanin-Zhorov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220395501Abstract: The invention relates to treatment of graft versus host disease (GVHD) using compounds that inhibit ROCK2. In preferred aspects, the present invention provides methods for the treatment of GVHD, including chronic GVHD (cGVHD) using compounds having the formulae I-XXV, as set forth herein.Type: ApplicationFiled: March 11, 2022Publication date: December 15, 2022Inventors: Alexandra Zanin-Zhorov, Bruce Robert Blazar, Ryan Flynn
-
Patent number: 11311541Abstract: The invention relates to treatment of graft versus host disease (GVHD) using compounds that inhibit ROCK2. In preferred aspects, the present invention provides methods for the treatment of GVHD, including chronic GVHD (cGVHD) using compounds having the formulae 1-XXV, as set forth herein.Type: GrantFiled: April 9, 2015Date of Patent: April 26, 2022Assignees: KADMON CORPORATION, LLC, REGENTS OF THE UNIVERSITY OF MINNESOTAInventors: Alexandra Zanin-Zhorov, Bruce Robert Blazar, Ryan Flynn
-
Publication number: 20210147391Abstract: The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of treating diseases and disorders involving inhibiting ROCK1 and/or ROCK2.Type: ApplicationFiled: June 26, 2020Publication date: May 20, 2021Inventors: Masha V. Poyurovsky, Ji-In Kim, Kevin G. Liu, Alexandra Zanin-Zhorov
-
Patent number: 10696660Abstract: The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of treating diseases and disorders involving inhibiting ROCK1 and/or ROCK2.Type: GrantFiled: January 18, 2019Date of Patent: June 30, 2020Assignee: Kadmon Corporation, LLCInventors: Masha V. Poyurovsky, Ji-In Kim, Kevin G. Liu, Alexandra Zanin-Zhorov
-
Publication number: 20190308953Abstract: The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of treating diseases and disorders involving inhibiting ROCK1 and/or ROCK2.Type: ApplicationFiled: January 18, 2019Publication date: October 10, 2019Inventors: Masha V. Poyurovsky, Ji-In Kim, Kevin G. Liu, Alexandra Zanin-Zhorov
-
Patent number: 10183931Abstract: The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of treating diseases and disorders involving inhibiting ROCK1 and/or ROCK2.Type: GrantFiled: November 10, 2017Date of Patent: January 22, 2019Assignee: Kadmon Corporation, LLCInventors: Masha Poyurovsky, Ji-In Kim, Kevin Liu, Alexandra Zanin-Zhorov
-
Publication number: 20180244657Abstract: The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of treating diseases and disorders involving inhibiting ROCK1 and/or ROCK2.Type: ApplicationFiled: November 10, 2017Publication date: August 30, 2018Inventors: Masha Poyurovsky, Ji-In Kim, Kevin Liu, Alexandra Zanin-Zhorov
-
Patent number: 9815820Abstract: The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of treating diseases and disorders involving inhibiting ROCK1 and/or ROCK2.Type: GrantFiled: October 7, 2013Date of Patent: November 14, 2017Assignee: Kadmon Corporation, LLCInventors: Masha Poyurovsky, Ji-In Kim, Kevin Liu, Alexandra Zanin-Zhorov
-
Publication number: 20170112832Abstract: The invention relates to treatment of graft versus host disease (GVHD) using compounds that inhibit ROCK2. In preferred aspects, the present invention provides methods for the treatment of GVHD, including chronic GVHD (cGVHD) using compounds having the formulae 1-XXV, as set forth herein.Type: ApplicationFiled: April 9, 2015Publication date: April 27, 2017Inventors: Alexandra ZANIN-ZHOROV, Bruce Robert BLAZAR, Ryan FLYNN
-
Publication number: 20150252025Abstract: The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of treating diseases and disorders involving inhibiting ROCK1 and/or ROCK2.Type: ApplicationFiled: October 7, 2013Publication date: September 10, 2015Inventors: Masha Poyurovsky, Ji-In Kim, Kevin Liu, Alexandra Zanin-Zhorov
-
Publication number: 20150157588Abstract: The present invention relates to the compound amino-phenyl-acetic acid octadec-(Z)-9-enyl ester, an enantiomer thereof or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising it, for use in the treatment of tumors and metastases, and to methods for treating a tumor or metastases comprising administering said compound to a subject in need thereof. The present invention particularly relates to said compound when it is dissolved in an ethanol solution.Type: ApplicationFiled: July 4, 2013Publication date: June 11, 2015Inventors: Irun R. Cohen, Meir Shinitzky, Raanan Margalit, Michal Cohen-Sfady, Alexandra Zanin-Zhorov
-
Publication number: 20140350078Abstract: The present invention relates to a method of identifying candidate compounds useful as chemotherapeutics or anti-infective compounds or anti-inflammatory drugs. This method involves providing a plurality of test compounds. The plurality of test compounds are incubated with human Regulatory T (Treg) cells expressing Disc-Large Homo log 1 (Dlgh1) or in which Dlgh1 is suppressed, where the Treg cells have an immunological synapse (IS). Test compounds which inhibit Dlgh1 expression, recruitment to the IS, and/or activity in the Treg cells are identified as candidate compounds potentially useful as chemotherapeutics or anti-infective compounds. Test compounds which enhance Dlgh1 recruitment to the IS and/or activity in the Treg cells are identified as candidate compounds potentially useful as anti-inflammatory drugs. The present invention also relates to methods of treating inflammatory conditions, cancers, and infectious diseases in a subject, as well as methods of inhibiting Treg cell activity.Type: ApplicationFiled: September 13, 2012Publication date: November 27, 2014Applicant: NEW YORK UNIVERSITYInventors: Michael Dustin, Alexandra Zanin-Zhorov
-
Publication number: 20140219979Abstract: The present invention provides novel uses for peptide p277—positions 437-460 of human heat shock protein 60 (HSP60)—in modulation of immune responses and inflammatory diseases. The invention further provides novel uses for HSP60 and p277 in the treatment or prevention of hepatic disorders. The invention discloses methods for treating, preventing or ameliorating the symptoms of T cell mediated inflammatory and autoimmune disorders, including hepatic disorders, which comprise administering to a subject in need thereof a composition comprising as an active ingredient an effective quantity of a molecule selected from: HSP60, p277, fragments, analogs, homologs and derivatives thereof, and nucleic acids encoding same. Also disclosed are T cell vaccination methods for treating or preventing T cell mediated disorders.Type: ApplicationFiled: March 21, 2014Publication date: August 7, 2014Applicant: Yeda Research and Development Co. Ltd.Inventors: Irun R. Cohen, Alexandra Zanin-Zhorov, Guy Tal, Francisco Quintana, Meirav Pisner, Ofer Lider
-
Patent number: 8691772Abstract: The present invention provides novel uses for peptide p277—positions 437-460 of human heat shock protein 60 (HSP60)—in modulation of immune responses and inflammatory diseases. The invention further provides novel uses for HSP60 and p277 in the treatment or prevention of hepatic disorders. The invention discloses methods for treating, preventing or ameliorating the symptoms of T cell mediated inflammatory and autoimmune disorders, including hepatic disorders, which comprise administering to a subject in need thereof a composition comprising as an active ingredient an effective quantity of a molecule selected from: HSP60, p277, fragments, analogs, homologs and derivatives thereof, and nucleic acids encoding same. Also disclosed are T cell vaccination methods for treating or preventing T cell mediated disorders.Type: GrantFiled: January 4, 2006Date of Patent: April 8, 2014Assignee: Yeda Research and Development Co. Ltd.Inventors: Irun R. Cohen, Alexandra Zanin-Zhorov, Guy Tal, Francisco Quintana, Meirav Pevsner, Osnat Lider, Lihi Lider
-
Publication number: 20120196919Abstract: Disclosed is a method for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and atherosclerosis. Specifically, the invention relates to a method of treating an immunological disorder or atherosclerosis in a patient comprising treating blood from the patient, or a defined component of said blood, with an inhibitor of PKC-theta ex vivo and then re-administering the treated blood to the patient.Type: ApplicationFiled: April 28, 2010Publication date: August 2, 2012Applicants: NEW YORK UNIVERSITY, BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Maryanne Brown, Michael Dustin, Alexandra Zanin-Zhorov
-
Publication number: 20110142814Abstract: The present invention provides methods for reducing tumor necrosis factor activation of regulatory T cells (Tregs), restoring the activity of defective Tregs, and enhancing the function of Tregs using Protein Kinase C theta (PKC-?) inhibitors. The enhancement in Treg function is of use in facilitating adoptive immunotherapy in the treatment of immunological disorders.Type: ApplicationFiled: December 15, 2010Publication date: June 16, 2011Applicant: New York UniversityInventors: Alexandra Zanin-Zhorov, Michael L. Dustin
-
Publication number: 20100003225Abstract: The present invention provides novel uses for peptide p277—positions 437-460 of human heat shock protein 60 (HSP60)—in modulation of immune responses and inflammatory diseases. The invention further provides novel uses for HSP60 and p277 in the treatment or prevention of hepatic disorders. The invention discloses methods for treating, preventing or ameliorating the symptoms of T cell mediated inflammatory and autoimmune disorders, including hepatic disorders, which comprise administering to a subject in need thereof a composition comprising as an active ingredient an effective quantity of a molecule selected from: HSP60, p277, fragments, analogs, homologs and derivatives thereof, and nucleic acids encoding same. Also disclosed are T cell vaccination methods for treating or preventing T cell mediated disorders.Type: ApplicationFiled: January 4, 2006Publication date: January 7, 2010Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD. at The Weizmann Institute of ScienceInventors: Irun R. Cohen, Alexandra Zanin-Zhorov, Guy Tal, Francisco Quintana, Meirav Pevsner, Ofer Lider, Osnat Lider, Lihi Lider